Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
AiCuris
AiCuris
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Ingredients
AiCuris initiates clinical development of AIC499, a novel resistance-breaking antibiotic
Programme supported by the Innovative Medicines Initiative
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
Can new discoveries prevent an antibiotic Armageddon?
Governments are waking up to the catastrophe of drug resistance and healthcare without antibiotics. But is extra funding the answer or could the pharma industry be doing more?
Research & Development
COMBACTE-MAGNET project aims to stimulate antibiotic development in Europe
Seven-year project brings together 33 European academic partners and five pharmaceutical companies
Regulatory
Antiviral agent – letermovir
Cytomegalovirus (CMV) can cause severe difficulties in patients with compromised immune systems, such as people with HIV infection or those who are undergoing organ or bone marrow transplantation
Subscribe now